Statement of Changes in Beneficial Ownership (4)
January 29 2021 - 5:35PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Steinmetz Nicole Franziska |
2. Issuer Name and Ticker or Trading Symbol
Mosaic ImmunoEngineering Inc.
[
CPMV
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Acting CSO |
|
(Last)
(First)
(Middle)
1537 SOUTH NOVATO BLVD., #5 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
1/29/2021 |
|
(Street)
NOVATO, CA 94947
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
| Common Stock | 1/29/2021 | | C | | 1641252 | A | (1) | 1641252 | D | |
| Common Stock | 1/29/2021 | | C | | 570870 | A | (1) | 570870 | I | By spouse. |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Series A Convertible Voting Preferred Stock | (1)(2) | 1/29/2021 | | C | | | 161000 | (1) | (2) | Common Stock | 1641252 | (1) | 0 | D | |
| Series A Convertible Voting Preferred Stock | (1)(2) | 1/29/2021 | | C | | | 56000 | (1) | (2) | Common Stock | 570870 | (1) | 0 | I | By spouse |
| Explanation of Responses: |
| (1) | Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021. |
| (2) | The Series A Convertible Voting Preferred Stock has no expiration date. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Steinmetz Nicole Franziska
1537 SOUTH NOVATO BLVD., #5
NOVATO, CA 94947 | X | X | Acting CSO |
|
Signatures
|
| /s/ Paul Lytle, as attorney-in-fact for Nicole Steinmetz | | 1/29/2021 |
| **Signature of Reporting Person | Date |
Mosaic ImmunoEngineering (PK) (USOTC:CPMV)
Historical Stock Chart
From May 2024 to Jun 2024
Mosaic ImmunoEngineering (PK) (USOTC:CPMV)
Historical Stock Chart
From Jun 2023 to Jun 2024
